HK1133601A1 - Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides - Google Patents

Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Info

Publication number
HK1133601A1
HK1133601A1 HK10101587.5A HK10101587A HK1133601A1 HK 1133601 A1 HK1133601 A1 HK 1133601A1 HK 10101587 A HK10101587 A HK 10101587A HK 1133601 A1 HK1133601 A1 HK 1133601A1
Authority
HK
Hong Kong
Prior art keywords
peptides
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Application number
HK10101587.5A
Other languages
English (en)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1133601A1 publication Critical patent/HK1133601A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
HK10101587.5A 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides HK1133601A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
HK08105026.9A HK1110529A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
HK1133601A1 true HK1133601A1 (en) 2010-04-01

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11106949.6A HK1152873A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK08105026.9A HK1110529A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK10101587.5A HK1133601A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK11106949.6A HK1152873A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK08105026.9A HK1110529A1 (en) 2005-02-28 2008-05-06 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Country Status (11)

Country Link
US (4) US7919099B2 (pt)
EP (4) EP2095822B1 (pt)
JP (3) JP4931154B2 (pt)
CY (1) CY1112867T1 (pt)
DK (3) DK1855707T3 (pt)
ES (3) ES2442294T3 (pt)
HK (3) HK1152873A1 (pt)
PL (3) PL1855707T3 (pt)
PT (3) PT2289533E (pt)
SI (3) SI2095822T1 (pt)
WO (1) WO2006093030A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270042B1 (en) 2002-09-12 2015-01-14 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
CN103784938A (zh) * 2007-02-16 2014-05-14 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
CA2158745C (en) 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
ATE319477T1 (de) 1995-08-03 2006-03-15 Univ Leiden Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
WO2003050140A1 (fr) 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
EP2270042B1 (en) * 2002-09-12 2015-01-14 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
JP5789820B2 (ja) 2015-10-07
ES2435650T3 (es) 2013-12-20
JP2008531463A (ja) 2008-08-14
US8257711B2 (en) 2012-09-04
US8663647B2 (en) 2014-03-04
JP2012102105A (ja) 2012-05-31
SI2289533T1 (sl) 2013-11-29
JP4843095B2 (ja) 2011-12-21
SI1855707T1 (sl) 2012-07-31
WO2006093030A1 (en) 2006-09-08
PL1855707T3 (pl) 2012-08-31
SI2095822T1 (sl) 2013-12-31
US20110250219A1 (en) 2011-10-13
HK1110529A1 (en) 2008-07-18
US20090214581A1 (en) 2009-08-27
DK2095822T3 (da) 2014-01-13
ES2442294T3 (es) 2014-02-11
EP1855707A1 (en) 2007-11-21
DK2289533T3 (da) 2013-12-02
US7919099B2 (en) 2011-04-05
US20120294877A1 (en) 2012-11-22
PL2289533T3 (pl) 2014-02-28
EP2289533A1 (en) 2011-03-02
ES2385396T3 (es) 2012-07-24
DK1855707T3 (da) 2012-07-16
JP4931154B2 (ja) 2012-05-16
JP2010265269A (ja) 2010-11-25
EP2095822A1 (en) 2009-09-02
PT1855707E (pt) 2012-05-25
EP2289533B1 (en) 2013-09-18
EP1855707B1 (en) 2012-04-04
EP2095822B1 (en) 2013-10-16
EP2289532A1 (en) 2011-03-02
US20140186381A1 (en) 2014-07-03
HK1152873A1 (en) 2012-03-16
PT2095822E (pt) 2013-12-09
PT2289533E (pt) 2013-12-10
PL2095822T3 (pl) 2014-03-31
CY1112867T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
HK1152873A1 (en) Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
HK1167325A1 (en) Antibodies against vascular endothelial growth factor receptor-1 -1
EP1699484A4 (en) HUMANIZED ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR
IL178070A (en) Antibiotic p-selectin antibodies and pharmaceuticals that include them
IL230645A (en) Antibodies against activin a or b and their use to promote bone growth
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
PL2272873T3 (pl) Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
EP1784142A4 (en) MUSCLES SKELETAL IMPLANT WITH BIOACTIVE LUG
IL182267A0 (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor
EP1760098A4 (en) BIOCOMPATIBLE MATERIAL
PL1838341T3 (pl) Kompozycja szczepionki obejmująca białko wiążące fibronektynę lub peptyd wiążący fibronektynę
EP1948676A4 (en) CONJUGATE BASED ON BLOOD PROTEIN AND BIOACTIVE SUBSTANCE
IL209870A0 (en) Mybl2 epitope peptides and vaccines containing the same
ZA200302872B (en) Graded Crystallization of container finishes.
EP1893233A4 (en) PEPTIDES AND THERAPEUTIC VACCINES
EP2321411A4 (en) MELK EPITOPEPEPTIDES AND VACCINES CONTAINING THEREOF
HK1157397A1 (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same rab6kifl/kif20a
PL375807A1 (pl) Podpora myśliwska
ZA200801874B (en) Antigenic peptides and their use
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
GB2417482B (en) Box or container support
GB0505093D0 (en) Tiana's bottle shaker
ZA200800566B (en) Therapeutic peptides and vaccines
GB0508726D0 (en) Polypeptide, vaccine and use thereof
PL1874712T3 (pl) Wytwarzanie jodku metylu znakowanego <sup>11</sup>C oraz radioligandu 11C GB67

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170217